Simplified Chinese
Our company has passed the quality assurance system inspection conducted by the Drug Administration.
Release date:
2017-11-27
Author:
Quality Assurance Department, Wang Xiaoli
Source:
Abstract
Recently, inspection teams from the Beijing Municipal Administration for Market Regulation and the Daxing District Administration for Market Regulation conducted a routine follow-up inspection at our company. The company’s General Manager, Zheng Haifa, Executive Deputy General Manager, Liu Jiankai, Quality Director, Li Xiangqun, and other relevant personnel accompanied the inspectors throughout the process.
The inspection team’s experts conducted a comprehensive review of the company’s quality assurance system by means of interviews, on-site visits, document reviews, and record examinations. In their final assessment, the experts concluded that the company’s quality assurance system is in compliance with the requirements of the relevant standards, expressing particular appreciation for the system’s thoroughness and practicality. They also provided specific recommendations and improvement measures to address the issues identified during the audit.
Quality is a timeless priority, and supervisory audits have no end—only a beginning. Beijing Minhai Biotechnology Co., Ltd. will continuously optimize its workflows, pursue ongoing improvements, rigorously control every stage of quality, ensure that each product meets both customer expectations and legal and regulatory requirements, and remain committed to safeguarding human health.

Keywords:
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09